Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders

NCT00632242 is registered in ClinicalTrials.gov with Archemix Corp. as lead sponsor.

NCT NCT00632242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00632242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders
Lead sponsor
Archemix Corp.
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
December 31, 2008
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

purpura, thrombotic thrombocytopenic, von willebrand disease type-2b